1426 related articles for article (PubMed ID: 23815902)
1. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
2. [Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib].
Huang XJ; Hu JD; Li JY; Jin J; Meng FY; Shen ZX; Liu T; Wu DP; Wang JM; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):889-95. PubMed ID: 23363742
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Hochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ; Facon T; Goldberg SL; Cervantes F; Niederwieser D; Silver RT; Stone RM; Hughes TP; Muller MC; Ezzeddine R; Countouriotis AM; Shah NP
Blood; 2007 Mar; 109(6):2303-9. PubMed ID: 17138817
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
Apperley JF; Cortes JE; Kim DW; Roy L; Roboz GJ; Rosti G; Bullorsky EO; Abruzzese E; Hochhaus A; Heim D; de Souza CA; Larson RA; Lipton JH; Khoury HJ; Kim HJ; Sillaber C; Hughes TP; Erben P; Van Tornout J; Stone RM
J Clin Oncol; 2009 Jul; 27(21):3472-9. PubMed ID: 19487385
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
Stein B; Smith BD
Clin Ther; 2010 May; 32(5):804-20. PubMed ID: 20685492
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Quintás-Cardama A; Cortes JE; O'Brien S; Ravandi F; Borthakur G; Liu D; Bleickardt E; Chen TT; Kantarjian HM
Cancer; 2009 Jul; 115(13):2912-21. PubMed ID: 19402171
[TBL] [Abstract][Full Text] [Related]
13. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Guilhot F; Apperley J; Kim DW; Bullorsky EO; Baccarani M; Roboz GJ; Amadori S; de Souza CA; Lipton JH; Hochhaus A; Heim D; Larson RA; Branford S; Muller MC; Agarwal P; Gollerkeri A; Talpaz M
Blood; 2007 May; 109(10):4143-50. PubMed ID: 17264298
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.
Klamova H; Faber E; Zackova D; Markova M; Voglova J; Cmunt E; Novakova L; Machova-Polakova K; Moravcova J; Dvorakova D; Michalova K; Brezinova J; Oltova A; Jarosova M; Cetkovsky P; Indrak K; Mayer J
Neoplasma; 2010; 57(4):355-9. PubMed ID: 20429627
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Hochhaus A; Müller MC; Radich J; Branford S; Kantarjian HM; Hanfstein B; Rousselot P; Kim DW; Lipton JH; Bleickardt E; Lambert A; Hughes TP
Leukemia; 2009 Sep; 23(9):1628-33. PubMed ID: 19641527
[TBL] [Abstract][Full Text] [Related]
18. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
19. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
